

Appendix A5. Netherlands disease reference list

Table 1.1 Data sources							
	Incidence	Prevalence	Survival	Mortality	Direct costs	Indirect costs	Utility weights
Diseases							
CHD	Pers comm Dr. Ineke van Dis; Senior Policy Advisor	Pers comm Dr. Ineke van Dis; Senior Policy Advisor	Derived from mortality & incidence	Pers comm Dr. Ineke van Dis; Senior Policy Advisor	(Nichols et al., 2012, Polder et al., 2002)	(Nichols et al., 2012, Polder et al., 2002)	(Vemer and Rutten-van Molken, 2010)
COPD	(Afonso et al., 2011)	(Vanfleteren et al., 2012)	Derived from mortality & incidence	(World Health Organisation, 2008)	(Suijkerbuijk et al., 2013)	UK proxy (Flack et al., 2007)	(Vemer and Rutten-van Molken, 2010)
IGT/IFG	Estimated from prevalence	(International Diabetes Federation, 2014)	n/a	n/a	Expert opinion by Dr. Hans van Hateren, GP with a special focus on diabetes (Hardenberg)	Assumption (zero)	Assumption (1.0)
Diabetes	(Ubink-Veltmaat et al., 2003)	(International Diabetes Federation, 2014)	n/a	n/a	(International Diabetes Federation, 2014)	(International Diabetes Federation, 2014, van der Heijden et al., 2014)	UK proxy (Sullivan et al., 2011)
Stroke	(Vaartjes et al., 2008)	(Truelsen et al., 2006)	Estimated from prevalence and mortality	(World Health Organisation, 2008)	(Hoogendoorn M et al., 2006)	(Nichols et al., 2012, Polder et al., 2002)	(Vemer and Rutten-van Molken, 2010)
Hypertension	Estimated from prevalence	Netherlands Morbidity Statistics 2011	n/a	n/a	(Polder et al., 2002)	(Nichols et al., 2012, Polder et al., 2002)	UK proxy (Sullivan et al., 2011)

Table. Relative risk references

	Relative risk: smoking	Relative risk: BMI
Diseases		
CHD	(A Dynamic Model for Health Impact Assessment (DYNAMO-HIA), 2015)	(Lobstein and Leach, 2010)
COPD	(A Dynamic Model for Health Impact Assessment (DYNAMO-HIA), 2015)	N/A
IGT	N/A	Estimated from Prevend (Jaccard A 2015)
Diabetes	N/A	Estimated from Prevend (Jaccard A 2015)
Stroke	(A Dynamic Model for Health Impact Assessment (DYNAMO-HIA), 2015)	(Lobstein and Leach, 2010)
Hypertension	Halperin 2008	

- A DYNAMIC MODEL FOR HEALTH IMPACT ASSESSMENT (DYNAMO-HIA). 2015. *United Kingdom vs2.0.6.zip* [Online]. National Institute for Public Health and the Environment. Available: <http://www.dynamo-hia.eu/> [Accessed 15/11/2014].
- AFONSO, A. S., VERHAMME, K. M., STURKENBOOM, M. C. & BRUSSELLE, G. G. 2011. COPD in the general population: prevalence, incidence and survival. *Respir Med*, 105, 1872-84.
- FLACK, S., TAYLOR, M. & TRUEMAN, P. 2007. Cost-Effectiveness of Interventions for Smoking Cessation Final Report. In: NICE (ed.). York: University of York.
- INTERNATIONAL DIABETES FEDERATION. 2014. *IDF Diabetes Atlas* [Online]. Available: https://www.idf.org/sites/default/files/Atlas-poster-2014_EN.pdf [Accessed 28/08/2015].
- LOBSTEIN, T. & LEACH, R. J. 2010. Workpackage 7: Overweight and Obesity Report on data collection for overweight and obesity prevalence and related relative risks. In: DYNAMO-HIA (ed.). International association for the study of obesity.
- NICHOLS, M., TOWNSEND, N., SCARBOROUGH, P., RAYNER, M., LEAL, J., LUENGO-FERNANDEZ, R. & GRAY, A. 2012. European cardiovascular disease statistics. In: LOGSTRUP, S. & O'KELLY, S. (eds.). Brussels and Sophia Antipolis: European Heart Network and European Society of Cardiology.
- POLDER, J., TAKKEN, J., MEERDING, W. J., KOMMER, G. J. & STOKX, L. J. 2002. *Cost of illness tool* [Online]. Bilthoven: National Institute for Health and Environment (RIVM). Available: <https://kostenvanziektentool.volksgezondheidenzorg.info/tool/english/> 2015].
- SUIJKERBUIJK, A. W., DE WIT, G. A., WIJGA, A. H., HEIJMANS, M., HOOGENDOORN, M., RUTTEN-VAN MOLKEN, M., MAURITS, E. E., HOOGENVEEN, R. T. & FEENSTRA, T. L. 2013. [Societal costs of asthma, COPD and respiratory allergy]. *Ned Tijdschr Geneesk*, 157, A6562.
- SULLIVAN, P. W., SLEJKO, J. F., SCULPHER, M. J. & GHUSHCHYAN, V. 2011. Catalogue of EQ-5D Scores for the United Kingdom. *Med Decis Making*, 31, 800-804.
- TAJIMA, R., KONDO, M., KAI, H., SAITO, C., OKADA, M., TAKAHASHI, H., DOI, M., TSURUOKA, S. & YAMAGATA, K. 2010. Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). *Clin Exp Nephrol*, 14, 340-8.
- TRUELSEN, T., PIECHOWSKI-JOZWIAK, B., BONITA, R., MATHERS, C., BOGOUSSLAVSKY, J. & BOYSEN, G. 2006. Stroke incidence and prevalence in Europe: a review of available data. *Eur J Neurol*, 13, 581-98.
- UBINK-VELTMAAT, L. J., BILO, H. J., GROENIER, K. H., HOUWELING, S. T., RISCHEN, R. O. & MEYBOOM-DE JONG, B. 2003. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). *Eur J Epidemiol*, 18, 793-800.
- VAARTJES, I., REITSMA, J. B., DE BRUIN, A., BERGER-VAN SIJL, M., BOS, M. J., BRETILER, M. M., GROBBEE, D. E. & BOTS, M. L. 2008. Nationwide incidence of first stroke and TIA in the Netherlands. *Eur J Neurol*, 15, 1315-23.
- VAN DER HEIJDEN, A. A., DE BRUIJNE, M. C., FEENSTRA, T. L., DEKKER, J. M., BAAN, C. A., BOSMANS, J. E., BOT, S. D., DONKER, G. A. & NIJPELS, G. 2014. Resource use and costs of type 2 diabetes patients receiving managed or protocolized primary care: a controlled clinical trial. *BMC Health Serv Res*, 14, 280.
- VANFLETEREN, L. E., FRANSSSEN, F. M., WESSELING, G. & WOUTERS, E. F. 2012. The prevalence of chronic obstructive pulmonary disease in Maastricht, the Netherlands. *Respir Med*, 106, 871-4.
- VEMER, P. & RUTTEN-VAN MOLKEN, M. P. 2010. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. *Value Health*, 13, 230-41.

WORLD HEALTH ORGANISATION. 2008. *Disease and injury country estimates* [Online]. Available: http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/ 2015].